CN1626205A - Preparation for external use of Chinese traditional medicine for treating gout and preparation method - Google Patents
Preparation for external use of Chinese traditional medicine for treating gout and preparation method Download PDFInfo
- Publication number
- CN1626205A CN1626205A CNA2004100404571A CN200410040457A CN1626205A CN 1626205 A CN1626205 A CN 1626205A CN A2004100404571 A CNA2004100404571 A CN A2004100404571A CN 200410040457 A CN200410040457 A CN 200410040457A CN 1626205 A CN1626205 A CN 1626205A
- Authority
- CN
- China
- Prior art keywords
- radix
- preparation
- chinese medicine
- material mixture
- medical material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 74
- 201000005569 Gout Diseases 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims description 30
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 55
- 239000000203 mixture Substances 0.000 claims description 35
- 238000002156 mixing Methods 0.000 claims description 32
- 239000012567 medical material Substances 0.000 claims description 30
- 239000000758 substrate Substances 0.000 claims description 23
- 239000000843 powder Substances 0.000 claims description 20
- 238000012856 packing Methods 0.000 claims description 18
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 17
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims description 14
- 238000003756 stirring Methods 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 11
- 238000010992 reflux Methods 0.000 claims description 11
- 238000007789 sealing Methods 0.000 claims description 9
- 238000007493 shaping process Methods 0.000 claims description 9
- 239000011505 plaster Substances 0.000 claims description 8
- 239000006071 cream Substances 0.000 claims description 6
- 239000009136 dragon's blood Substances 0.000 claims description 6
- 239000003292 glue Substances 0.000 claims description 6
- 239000002674 ointment Substances 0.000 claims description 6
- 238000011084 recovery Methods 0.000 claims description 6
- 239000000853 adhesive Substances 0.000 claims description 4
- 230000001070 adhesive effect Effects 0.000 claims description 4
- 239000004744 fabric Substances 0.000 claims description 4
- 239000011347 resin Substances 0.000 claims description 4
- 229920005989 resin Polymers 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 11
- 239000000463 material Substances 0.000 abstract description 11
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 1
- 244000247747 Coptis groenlandica Species 0.000 abstract 1
- 235000002991 Coptis groenlandica Nutrition 0.000 abstract 1
- 241000972673 Phellodendron amurense Species 0.000 abstract 1
- 241000245665 Taraxacum Species 0.000 abstract 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 abstract 1
- 229940116229 borneol Drugs 0.000 abstract 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 48
- 208000002193 Pain Diseases 0.000 description 23
- 230000036407 pain Effects 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 19
- 229940079593 drug Drugs 0.000 description 19
- 206010070834 Sensitisation Diseases 0.000 description 16
- 230000008313 sensitization Effects 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 206010015150 Erythema Diseases 0.000 description 13
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical group C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 13
- 231100000321 erythema Toxicity 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 206010030113 Oedema Diseases 0.000 description 12
- 230000008961 swelling Effects 0.000 description 10
- 206010040880 Skin irritation Diseases 0.000 description 9
- 231100000475 skin irritation Toxicity 0.000 description 9
- 230000036556 skin irritation Effects 0.000 description 9
- 238000012377 drug delivery Methods 0.000 description 8
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 7
- 230000003203 everyday effect Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 208000000114 Pain Threshold Diseases 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000037040 pain threshold Effects 0.000 description 6
- 231100000572 poisoning Toxicity 0.000 description 6
- 230000000607 poisoning effect Effects 0.000 description 6
- 201000004624 Dermatitis Diseases 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 235000013599 spices Nutrition 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 241000700199 Cavia porcellus Species 0.000 description 4
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- -1 glycine aluminum Chemical compound 0.000 description 4
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 3
- 229920002799 BoPET Polymers 0.000 description 3
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical group C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 3
- 239000005041 Mylar™ Substances 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- 230000036592 analgesia Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 230000004856 capillary permeability Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940000406 drug candidate Drugs 0.000 description 3
- 239000003777 experimental drug Substances 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 229960000482 pethidine Drugs 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000007480 spreading Effects 0.000 description 3
- 238000003892 spreading Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 240000006409 Acacia auriculiformis Species 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- HDYRYUINDGQKMC-UHFFFAOYSA-M acetyloxyaluminum;dihydrate Chemical compound O.O.CC(=O)O[Al] HDYRYUINDGQKMC-UHFFFAOYSA-M 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 2
- 229940009827 aluminum acetate Drugs 0.000 description 2
- 230000002052 anaphylactic effect Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 239000010238 camphora Substances 0.000 description 2
- 229940025250 camphora Drugs 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000000174 gluconic acid Substances 0.000 description 2
- 235000012208 gluconic acid Nutrition 0.000 description 2
- 108010084652 homeobox protein PITX1 Proteins 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 229960001047 methyl salicylate Drugs 0.000 description 2
- 230000001617 migratory effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001047 pyretic effect Effects 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 231100000456 subacute toxicity Toxicity 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002519 Animal scratch Diseases 0.000 description 1
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010051814 Eschar Diseases 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 231100000333 eschar Toxicity 0.000 description 1
- 229960003699 evans blue Drugs 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000008558 metabolic pathway by substance Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
An externally-applied Chinese medicine in the form of picking for treating gout is prepared from 5 Chinese-medicinal materials including phellodendron bark, coptis root, dandelion herb, borneol, etc. Its advantages are high curative effect and no toxic by-effect.
Description
Technical field: the present invention is a kind of Chinese medicine for external application for the treatment of gout and preparation method thereof, belongs to the field of traditional Chinese medicine technology.
Background technology: gout, modern medicine are thought purine substance metabolism disorder in the body, and uric acid is deposited on articular cavity and the joint of the lower extremity red and swollen heat pain that causes.Because of traditional medicine think gout be the wet visitor of wind and cold in muscles and bones, and its cold-evil is strongly fragrant and stagnation of pathogenic heat causes the meridians blood vessels obstructed, causes red and swollen heat pain.This disease is mainly in the young and the middle aged, and its sickness rate is ascendant trend year by year at present.Still the definite Chinese medicine preparation reliably of inefficacy at present.The Chinese patent communique discloses that application number is 971073945, name is called: the Chinese medicine preparation of treatment gout; Be 981216188 with application number, name is called: a kind of Chinese medicine for the treatment of goat; We have carried out some experiments with these two kinds of medicines; Found the problem that they exist: they all are that oral formulations and result of use are unsatisfactory.Owing to be oral formulations, so the management procedure more complicated of producing and selling, cost is higher, the price height that puts goods on the market, and the patient is unwilling to accept; Oral formulations more or less has certain toxic and side effects to human body in addition; This also is one of patient's reason of being unwilling to accept; Be exactly their formation more complicated in addition; Many ingredients can influence therapeutic effect, strengthen the cost of medicine simultaneously, also can make the quality of production be difficult to be effectively controlled.
Summary of the invention: the objective of the invention is to: a kind of Chinese medicine for external application for the treatment of gout and preparation method thereof is provided, this Department of Pharmacy forms with suitable substrate and the some Chinese medicine composition with therapeutical effect, extract medical material with scientific method processing, fill in the skeleton that is stated from substrate, paster substrate and skin intermiscibility are good, helping drug molecule passes through, drug release is slow, administration is steady, can alleviate the red, swollen, hot, bitterly of local joint rapidly, and is easy to use, zest is little, do not have toxic and side effects, medicine is cheap simultaneously, and therapeutic effect is good.The present invention is achieved in that according to components by weight percent and calculates that it mainly is prepared from by Cortex Phellodendri 400-800, Rhizoma Coptidis 50-80, Herba Taraxaci 300-700, Radix Achyranthis Bidentatae 400-800, Borneolum Syntheticum 40-80.Its preparation method is: get Cortex Phellodendri, Radix Achyranthis Bidentatae, Herba Taraxaci with the alcohol reflux of 10 times of amounts 40%～80% 2 times, each 2 hours, filter, merging filtrate, reclaim the thick paste of ethanol and simmer down to relative density 1.2, put coldly, Rhizoma Coptidis powder is broken into powder and Borneolum Syntheticum grinds to fusing, with the thick paste mixing that obtains, get medical material mixture, standby; With standby medical material mixture and substrate mixing, fully stirring and evenly mixing is coated with and spreads or roll, and after the shaping, cuts into the sheet of certain specification, packing, and sealing, packing is promptly.
Specifically: the external preparation among the present invention, calculate according to components by weight percent, it mainly is prepared from by Cortex Phellodendri 400-800, Rhizoma Coptidis 50-80, Herba Taraxaci 300-700, Radix Achyranthis Bidentatae 400-800, Borneolum Syntheticum 40-80, Herba Portulacae 300-700, the flying dragon blood palm 300-700, Radix Musae 400-800, Mentholum 40-80.
Its preparation method: get Cortex Phellodendri, Radix Achyranthis Bidentatae, Herba Taraxaci, Herba Portulacae, Radix Toddaliae Asiaticae, Radix Musae with the alcohol reflux of 10 times of amounts 40%～80% 2 times, each 2 hours, filter, merging filtrate, reclaim the thick paste of ethanol and simmer down to relative density 1.2, put coldly, Rhizoma Coptidis powder grinds to fusing with Borneolum Syntheticum, Mentholum after being broken into powder, with the thick paste mixing that obtains, get medical material mixture, standby; With standby medical material mixture and substrate mixing, fully stirring and evenly mixing is coated with and spreads or roll, and after the shaping, cuts into the sheet of certain specification, packing, and sealing, packing is promptly.
The preferred Chinese medicine for external application of the present invention: it is mainly made by Cortex Phellodendri 500g, Rhizoma Coptidis powder 50g, Radix Achyranthis Bidentatae 500g, Herba Taraxaci 400g, Herba Portulacae 400g, Venenum Bufonis 20g, Borneolum Syntheticum 40g, Mentholum 40g, Radix Toddaliae Asiaticae 400g, Radix Musae 500g.
External preparation described in the present invention comprises: patch, plaster, cataplasma, crust cloth cream, inferior quick glue unguentum, rubber-emplastrum, transdermal patch, gel adhesive.
Concrete preparation method is: get Cortex Phellodendri, Radix Achyranthis Bidentatae, Herba Taraxaci, Herba Portulacae, Radix Toddaliae Asiaticae, Radix Musae with the alcohol reflux of 10 times of amounts 40%～80% 2 times, each 2 hours, filter, merging filtrate, reclaim the thick paste of ethanol and simmer down to relative density 1.2, put coldly, Venenum Bufonis is dissolved in ethanol and Rhizoma Coptidis powder, Borneolum Syntheticum, Mentholum grind to fusing, with the thick paste mixing that obtains, get medical material mixture, standby; With standby medical material mixture and substrate mixing, fully stirring and evenly mixing is coated with and spreads or roll, and after the shaping, cuts into the sheet of certain specification, packing, and sealing, packing is promptly; Among the present invention: with the hydrophilic high molecular material is substrate, adds suitable filler (Kaolin, bentonite, zinc oxide, titanium dioxide); Firming agent or cross-linking agent (aluminium oxide, aluminum/EDTA, aluminum sulfate, aluminum acetate, glycine aluminum); Cross-linking regulator (citric acid, tartaric acid, gluconic acid, EDTA); Wetting agent (glycerol, sorbitol, propylene glycol); Percutaneous absorption enhancer (methyl salicylate, Camphora, Mentholum, plant extract) stirring and evenly mixing, with standby medical material mixture and substrate mixing, abundant stirring and evenly mixing, will mount respectively material, medical mylar and spice are packed in the patch spreading equipment, adjuvant rolls.After the shaping, cut into the sheet of certain specification, microwave sterilizating, packing, sealing, packing is promptly.According to the technology of existing pharmaceuticals industry, the medical material mixture that obtains can be become the plaster preparation according to prior art for preparing.Also can be with the medical material mixture that obtains according to prior art for preparing Cheng Babu (cream) agent.Can also be substrate according to prior art with rubber, resin glue or pressure sensitive adhesive with the medical material mixture that obtains, be made into paster.It is the yellowish-brown paster that the gel of the present invention's preparation pastes product, and special flavour of a drug are arranged.Be affixed on the affected part outward, subsides in a day, the careful usefulness of skin allergy person; Also the present invention can be extracted, blended Chinese medical concrete directly applies in the affected part and treats.
The present invention can become the plaster preparation according to prior art for preparing with the medical material mixture that obtains, cataplasma or crust cloth cream, or be substrate with resin glue or pressure sensitive adhesive, be made into paster, with rubber substrate, be made into paster, gel adhesive.
In development process: we find: use basic side just can better treat the gout disease, can strengthen the effect that red heat swells and ache of eliminating and add Herba Portulacae; Add the effect that flying dragon blood is slapped can increase reducing swelling and alleviating pain; Add Radix Musae and can strengthen the clearing away heat-damp and promoting diuresis effect, add the Herba Menthae brain-capacity and strengthen the clearing away heat to alleviate pain effect, add Venenum Bufonis and can accelerate treatment speed, reduce treatment time.
Through overtesting, we find that the present invention preferably is prepared into the external-use gel patch, use more convenient, health like this, and effective drug duration is more permanent.
Compared with prior art: the present invention has the effect of heat clearing away, detumescence, pain relieving, dampness removing.Be used for diseases such as local red, swollen, hot, pain such as neck that gouty arthritis and aseptic inflammation cause, shoulder, waist, lower limb, more significant effect is arranged; External medicine preparation provided by the invention system is that main matrix forms with the some Chinese medicine composition with therapeutical effect with hydrophilic soluble macromolecular material, extract medical material with scientific method processing, fill in the skeleton that is stated from substrate, paster substrate and skin intermiscibility are good, helping drug molecule passes through, drug release is slow, administration is steady, can alleviate the red, swollen, hot, bitterly of local joint rapidly, easy to use, zest is little, there is not toxic and side effects, medicine is cheap simultaneously, and therapeutic effect is good, has reached the purpose of invention.
Side of the present invention separates: gout belongs to the category of Chinese medicine arthromyodynia, and is similar with pyretic arthralgia in the arthromyodynia, severe and migratory arthralgia, severe and migratory arthralgia etc.Primary disease is invaded human body mainly due to damp and hot heresy, the meridians impatency, and QI-blood circulation is not smooth, causes muscle, muscles and bones, joint red, swollen, hot, bitterly, and it is unfavorable to take action; Later stage arthroncus, pain, or stiff deformity.We are formed by Triple Magic Powder plus-minus, Cortex Phellodendri big bitter Great Cold in the side, can rush down damp and hot, dampness is evil, the heresy of relieving inflammation or internal heat, separate fire-toxin, detumescence pain, is monarch drug; The Rhizoma Coptidis powder bitter cold can clearing away heat-fire, the dampness detoxifcation, and Herba Taraxaci is cold, can dampness removing heat, separate fire-toxin, detumescence pain, and the hot temperature row that looses of Venenum Bufonis kindly pulls out the wind-fire pyretic toxicity, is ministerial drug; The Radix Achyranthis Bidentatae blood circulation promoting and blood stasis dispelling, the meridian dredging, sharp joint, detumescence pain, the Mentholum perfume (or spice) that disappears is walked to scurry, and walks the flesh table outward, and interior muscles and bones can dispelling wind heat, the stasis of loosing, and Radix Musae, Herba Portulacae are cold in nature: as heat-clearing and toxic substances removing, dampness removing effect to be arranged, be adjuvant drug; The hot perfume (or spice) of Borneolum Syntheticum is walked to scurry, and air supporting is flown upward, and thorough thoroughly do not reach nowhere down can lead to and be jammed, keep away foul, heat radiation and save, and flying dragon blood is slapped, subduing swelling and detoxicating, and wind-expelling pain-stopping is messenger drug.Ten flavor medicines phases 5, the power of playing heat clearing away, detumescence, pain relieving, dampness removing altogether.
In order to prove effectiveness of the present invention, the inventor has carried out a series of experiments.
In order to estimate its safety, using for the clinical safety of this medicine provides foundation, and we have carried out relevant toxicity research to this gout external use plaster provided by the invention.
Experiment material
One, medicine
External use plaster, the every subsides of clinical application contain Chinese medical concrete 3.7g, and every 100g extractum contains Chinese medicine crude drug 420g.Because of these subsides be Chinese medicinal ointment mix with pressure sensitive adhesive the coating form, historical facts or anecdotes is tested and is selected for use Chinese medical concrete to carry out, experimental drug is provided by department of pharmacy of Guiyang College of Traditional Chinese Medicine system chamber of grinding.
Two, animal
Albino guinea-pig, white rabbit are provided by the Guiyang Medical College Experimental Animal Center.
Method and result:
One, acute toxicity test
20 of Cavia porcelluss, 200～250g, male and female half and half are divided into intact skin administration group (10 of animals) at random, damaged skin administration group (10 of animals).Preceding 24 hours of medicine is got hair with back part of animal, and animal all scratches to oozing of blood degree of being with scalpel in the unhairing district unhairing area 5 * 8cm damaged skin.Two treated animals all smear the Chinese medical concrete of this patch of preparation in the unhairing district, and wrapping is fixing.Administration every day 1 time, continuous 14 days.Observe poisoning manifestations and the death condition of animal every day.
Result:, do not see that intact skin and damaged skin animals administer have poisoning and dead with continuous 14 days percutaneous drug deliveries of the Chinese medical concrete of this patch.
Two, subacute toxicity test
20 of Cavia porcelluss, 200～250g, male and female half and half are divided into intact skin administration group (10 of animals) at random.Damaged skin administration group (10 of animals).Preceding 24 hours of administration, with the back part of animal unhairing, unhairing area 5 * 8cm, the damaged skin animal all scratches oozing of blood degree of being in the unhairing district with scalpel.Two treated animals all smear the Chinese medical concrete of this patch in the unhairing district, and wrapping is fixing.Administration every day 1 time, continuous 14 days.Observe poisoning manifestations and the death condition of animal every day.
Result:, do not see that intact skin and damaged skin animals administer have poisoning manifestations and death with continuous 14 days percutaneous drug deliveries of the Chinese medical concrete of this patch.
Three, skin irritation test
10 of rabbit, 2.0～2.5kg is divided into intact skin administration group (3 of animals) at random, intact skin contrast (2 of animals), damaged skin contrast (2 of animals).Preceding 24 hours of medicine, with the back part of animal unhairing, unhairing area 10 * 12cm, the damaged skin animal scratches to oozing of blood degree of being with scalpel in the unhairing district, the administration treated animal is all smeared the Chinese medical concrete of this patch in the unhairing district, control animals is all smeared the equivalent pressure sensitive adhesive, hands over wrapping fixing.Administration every day 1 time, continuous 14 days, observe every day 1 time, by " skin irritation reaction standards of grading " and " skin irritation intensity evaluation standard " Chinese medical concrete of this patch is carried out skin irritation evaluation (seeing Table 1,2) drug withdrawal day execution animal, the bark fetching skin is done the pathology histological examination.
The result: the Chinese medical concrete of this patch does not see that in intact skin damaged skin animal multiple dosing erythema and edema appear in rabbit skin, and skin irritation reaction scoring is 0, and the skin irritation intensity evaluation belongs to nonirritant; Damaged skin administration group and damaged skin matched group compare, process time of occurrence basically identicals such as the incrustation of breakage skin, decrustation, recovery from illness, no significant difference between the two; Dermatological histology checks end discovery pathological change.
Four, skin anaphylactic test
30 of Cavia porcelluss, 250～300g, male and female half and half are divided into this patch group, blank group, positive controls at random.Preceding 24 hours of medicine, back part of animal both sides unhairing, every side unhairing area 3 * 3cm is in unhairing district, back part of animal left side.This patch group smears the Chinese medical concrete of this patch, and the blank group smears the equivalent pressure sensitive adhesive, and positive controls smears 10% 2.4-dinitrochlorobenzene and carries out sensitization, and wrapping is fixed 6 hours after the administration, seals off.And in the 7th day and the 14th day, respectively again with method sensitization 1 time, sensitization is 3 times altogether, after the last sensitization the 14th day, three treated animals right side, back unhairing district respectively smear the Chinese medical concrete of this patch, remove residue in the unhairing district, observe at once with warm water, and observed again, this patch is carried out the skin allergy evaluation by " skin allergy standards of grading " and " sensitization rate criteria for classification " in 24,48,72 hours.Wind table 3,4.
The result: this patch group, blank group, positive controls skin allergy are respectively 0,0,3.8, and sensitization rate branch is being respectively 0%, 0%, 100%; Sensitivity response intensity is respectively weak sensitization, weak sensitization, extreme sensitization.
Table 1 skin irritation reaction standards of grading
The irritant reaction score value
Erythema:
No erythema 0
Inadequate visible 1
Moderate erythema 2
Severe erythema 3
The aubergine erythema also has eschar to form 4
Edema forms:
No edema 0
Inadequate visible 1
Cutaneous protuberance profile clear 2
Edema about 1mm of protuberance and expanded range 4
Total mark 8
Table 2 skin irritation intensity standards of grading
The intensity score value
Non-stimulated＜0.5
Slight stimulation＜2.0
Moderate thorn trip＜6.0
Strong stimulation＜6.0
Table 3 skin allergy standards of grading
The dermoreaction score value
Erythema:
No erythema 0
Slight erythema 1
Moderate erythema 2
Severe erythema 3
Edematous erythema 4
Edema forms:
No edema 0
Mild edema 1
Intermediate edema 2
The severe edema 3
Total mark 7
Table 4 sensitization rate criteria for classification
Sensitization rate (%) response strength
0～10 weak sensitization
20～30 slight sensitizations
40～60 moderate sensitizations
70～80 height sensitizations
90～100 extreme sensitizations
Find out by experiment:
1, percutaneous drug delivery acute toxicity test: percutaneous drug delivery of the Chinese medical concrete of this patch does not cause that poisoning manifestations and death appear in animal.The experimental result performance, percutaneous drug delivery of the Chinese medical concrete of this patch is safe.
2, percutaneous drug delivery subacute toxicity test: continuous 14 days of the Chinese medical concrete percutaneous drug delivery of this patch, do not cause that poisoning manifestations and death appear in animal, the experimental result performance, continuous 14 days of the Chinese medical concrete dermatologic of this patch, safe.
3, skin irritation test: Chinese medical concrete skin single administration of this patch and skin multiple dosing, do not see that erythema and edema appear in animal, do not influence wound healing, fail to cause dermal pathology Histological change.Result's performance, the Chinese medical concrete of this patch belongs to non-stimulated character.
4, skin anaphylactic test: the Chinese medical concrete of this patch fails to cause the animal skin anaphylaxis.The result shows that the Chinese medical concrete of this patch belongs to the nonirritant material.
The zoopery results suggest: the Chinese medical concrete of this patch belongs to nonirritant material, non-allergenic substance, clinical employing percutaneous drug delivery approach, used medicine Ji amount and all course of treatment toxicity little, safe.
Pharmacodynamics test research:
Experiment material
One, medicine
Patch provided by the invention, the every subsides of clinical application contain Chinese medical concrete 3.7g, and every 100g extractum contains Chinese medicine crude drug 420g.Because of this patch be Chinese medical concrete mix with pressure sensitive adhesive the coating form, historical facts or anecdotes is tested and is selected for use Chinese medical concrete to carry out, as required, experimental drug is mixed with Chinese medical concrete the suspension of three kinds of concentration: the every 100g of high concentration contains Chinese medicine crude drug 420g.The middle every 100g of concentration contains Chinese medicine crude drug 210g.The every 100g of low concentration contains Chinese medicine crude drug 105g.Experimental drug is provided by pharmacy teaching and research room of department of pharmacy of Guiyang College of Traditional Chinese Medicine.
Two, animal
Kunming mouse, rat is provided by the Guiyang Medical College Experimental Animal Center wistar kind.
Method and result
One, mice analgesic test
1, formaldehyde method analgesic test
70 of mices, 18-22g male and female half and half are divided into 5 groups at random: the high dense high group of the Chinese medical concrete of this patch, middle concentration group, low concentration group, pethidine group (25mg/kg).Matched group (giving the equivalent pressure sensitive adhesive).Except that pethidine treated animal intraperitoneal injection, all the other treated animals are smeared medicine or tester in left and right sides metapedes, behind the medicine 15 minutes, the right back sufficient subcutaneous injection 2.5% formaldehyde 0.03ml of every Mus, and repaste medicine 1 time, observe immediately that mice licks right back sufficient number of times in 15 minutes, test data adopts the t check to handle, down with.
The result: the Chinese medical concrete high concentration PARA FORMALDEHYDE PRILLS(91,95) of this patch causes pain to be had significant analgesia role, mice to lick right back sufficient number of times obviously to reduce, with matched group relatively, p＜0.05 sees Table 1.
2, mouse writhing method analgesic test
70 of mices, 18-22g, male and female half and half are divided 5 groups: the Chinese medical concrete high concentration group of this patch, middle concentration group, low concentration group, pethidine group (25mg/kg) at random.Matched group (giving the equivalent pressure sensitive adhesive).Except that pethidine treated animal intraperitoneal injection, all the other treated animals are smeared medicine or tester in abdominal part.Behind the medicine 15 minutes, every Mus lumbar injection 0.6% acetic acid 0.2ml, and the repaste medicine is observed in 15 minutes mice for 1 time immediately and is turned round number of times.
The result: the Chinese medical concrete high concentration Dichlorodiphenyl Acetate of this patch causes pain significant analgesia role.The mouse writhing number of times obviously reduces, and compares p＜0.05 with matched group.See Table 2
3, mice hot-plate analgesic test
The 500ml beaker is put into water bath with thermostatic control, make the beaker bottom contact water surface.Regulate water temperature, make it to be constant at 55+0.5 ℃, after the beaker bottom heating promptly as heat stimulus.Get some of the male and female mices of body weight 18-22g, put into the beaker that has heated successively and reaffirm choosing, record is from putting into beaker to time (second) of needing behind metapedes pain threshold as this Mus occurring licking, all mices that did not occur licking metapedes in 30 seconds are considered as defective, give it up, get 60 of the qualified pain threshold normal mouses of screening, measure the pain threshold of every Mus once more with method.With the meansigma methods of twice threshold of pain of the gained pain threshold before as this Mus administration.At random this batch animal is divided into 5 groups: the Chinese medical concrete concentration group of this patch, middle concentration group, low concentration group.Pethidine group (25mg/kg), matched group (giving the equivalent pressure sensitive adhesive).Except that pethidine treated animal intraperitoneal injection, all the other treated animals all in abdominal part and about foot smear medicine or tester.After the administration 30,60,90, minute.Mice is put into the beaker that has heated successively, measure the pain threshold of every mice respectively.Pain threshold as mice after the administration surpasses 60 seconds, then stops test, by 60 seconds, in case animal is scalded.The pain reaction latent time of record mice, and press and calculate threshold of pain raising percentage rate:
The result: the Chinese medical concrete high concentration of this patch, middle concentration causes pain to hot plate to be had significant analgesia role, mice to react latent time bitterly obviously to prolong, the mice threshold of pain is improved percentage rate and is obviously increased, with matched group relatively, P＜0.25, P＜0.01 see Table 3,4.
Two, antiinflammatory test
1, Chinese People's Anti-Japanese Military and Political College Mus foot swelling test
2, rat is 50,200-250g, and male and female half and half are divided into the Chinese medical concrete high concentration group of this patch, middle concentration group, low concentration group, fluocinonide group (0.025% ointment), matched group (giving the equivalent pressure sensitive adhesive) at random.Every Mus is smeared administration 1 time prior to metapedes, in right back whole plantar subcutaneous injection 1% carrageenin 0.1ml, smears medicine for immediately right back foot behind the 15min.Respectively at measuring the whole sole of the foot girth in back about every Mus after the administration in 1,2,3,4 hour, as the swelling degree, smear medicine for again respectively after each the measurement the right back foot of rat with two sufficient girth differences.
The result: the Chinese medical concrete high concentration of 2,3,4 hours these patches has the obvious suppression effect to rat paw edema behind the medicine, compares p＜0.05 with matched group.See Table 5.
2, anti-mice auricular concha swelling test
60 of mices, 18-22g, male and female half and half are divided into the Chinese medical concrete high concentration group of this patch, middle concentration group, low concentration group, fluocinonide group (0.025% ointment), matched group (giving the equivalent pressure sensitive adhesive) at random.Every Mus auris dextra shell melted paraxylene 0.03ml, the auris dextra shell is smeared administration behind the 30min.2h behind the medicine cuts left and right sides auricular concha, gets auricle with the 8mm card punch, with two auricle weight differences as the swelling degree.
The result: swelling has the obvious suppression effect to the Chinese medical concrete high concentration of this patch to the mice auricular concha, compares with matched group, and P＜0.05 sees Table 6.
3, to the influence of mouse peritoneal capillary permeability
60 of mices, 18-22g male and female half and half are divided into the Chinese medical concrete high concentration group of this patch, middle concentration group, low concentration group, fluocinonide group (0.025% ointment), matched group (giving the equivalent pressure sensitive adhesive) at random.Smear relative medicine or tester after the animal abdominal part unhairing, every day 1 time, continuous 7 days.After the last administration 30 minutes, every caudal vein was injected 0.5% azovan blue 0.1ml/10g.And lumbar injection 0.6% acetic acid 0.2ml/ only puts to death animal after 20 minutes immediately, cuts off the abdominal cavity, use normal saline flushing, collects the abdominal cavity washing liquid, adjusts volume and manages to 10ml/, gets supernatant in 721 type spectrophotometer 590nm places mensuration optical density (OD) after centrifugal.
The result: the Chinese medical concrete high concentration of this patch can obviously be made a price reduction the mouse peritoneal capillary permeability, compares with matched group, and P＜0.05 sees Table 7.
This patch of table 1 is to the inhibitory action of licking foot reaction (X ± SD)
The group number of animals is licked metapedes number of times P value suppression ratio (%)
Matched group 14 32.23 ± 5.63
High concentration group 14 15.21 ± 6.65＜0.05 53
Middle concentration group 14 30.84 ± 8.35＞0.05 4
Low concentration group 14 29.85 ± 8.65＞0.05 7
Pethidine group 14 0.00 ± 0.00＜0.001 100
The inhibitory action to writhing response of this patch of table 2 (X ± SD)
The group number of animals is licked metapedes number of times P value suppression ratio (%)
Matched group 14 59.64 ± 7.88
High concentration group 14 20.43 ± 9.21＜0.05 66
Middle concentration group 14 47.64 ± 8.96＞0.05 20
Low concentration group 14 40.87 ± 9.87＞0.05 31
Pethidine group 14 0.00 ± 0.00＜0.001 100
This patch of table 3 pain is reacted the influence (X ± SD) of latent time
Pain is reacted latent time (S)
The group number of animals
Behind the medicine prodrug 30 minutes 60 minutes 90 minutes
Matched group 12 19.29 ± 8.67 22.82 ± 9.29 24.66 ± 8.75 25.71 ± 9.59
High concentration group 12 19.48 ± 8.94 32.54 ± 8.55
*37.56 ± 8.62
*36.58 ± 9.85
*
Middle concentration group 12 19.78 ± 8.37 24.81 ± 8.65 21.85 ± 9.58 25.65 ± 9.25
Low concentration group 12 19.85 ± 8.93 21.74 ± 5.95 24.28 ± 9.98 22.47 ± 8.86
Pethidine group 12 19.69 ± 9.49 42.56 ± 8.84
* *51.55 ± 8.68
* *50.46 ± 9.80
* *
*Compare with matched group,
*P＜0.05
*P＜0.01
* *P＜0.001 (down together)
This patch of table 4 percentile influence is improved in the threshold of pain
Percentage rate (%) is improved in the threshold of pain
The group number of animals
30 60 90 (min) behind the medicine
Matched group 12 18 28 33
High concentration group 12 67 93 88
Middle concentration group 12 25 10 30
Low concentration group 12 10 22 13
Pethidine group 12 16 102 156
The influence to rat paw edema of this patch of table 5 (X ± S)
Group number of animals swelling degree (cm)
1h 2h 3h 4h
Matched group 10 1.48 ± 0.53 1.54 ± 0.67 1.49 ± 0.44 1.46 ± 0.59
High concentration group 10 1.26 ± 0.45 0.89 ± 0.26
*0.92 ± 0.54
*0.84 ± 0.39*
Middle concentration group 10 1.27 ± 0.57 1.38 ± 0.23 1.40 ± 0.34 1.43 ± 0.82
Low concentration group 10 1.37 ± 0.72 1.55 ± 0.34 1.42 ± 0.64 1.41 ± 0.54
Pethidine group 10 0.88 ± 0.52
* *J0.76 ± 0.44
* *0.74 ± 0.35
* *0.71 ± 0.56
* *
The influence to the swelling of mice auricular concha of this patch of table 6
The resistance rate is counted in the swelling of group number of animals
(only) be (%) (mg)
Matched group 12 7.23 ± 1.56
High concentration group 12 3.73 ± 1.64
*48
Middle concentration group 12 6.24 ± 1.86 13
Low concentration group 12 6.96 ± 1.57 4
Pethidine group 12 2.45 ± 1.84
* *66
The influence to capillary permeability of this patch of table 7 (X ± S)
Group number of animals OD P value
Matched group 12 1.56 ± 0.08
High concentration group 12 0.80 ± 0.05＜0.05
Middle concentration group 12 1.28 ± 0.06＞0.05
Low concentration group 12 1.09 ± 0.08＞0.05
Pethidine group 12 0.42 ± 0.07＜0.01
The specific embodiment:
Embodiments of the invention 1: take by weighing Cortex Phellodendri 500g, Rhizoma Coptidis powder 50g, Radix Achyranthis Bidentatae 500g, Herba Taraxaci 400g, Herba Portulacae 400g, Venenum Bufonis 20g, Borneolum Syntheticum 40g, Mentholum 40g, Radix Toddaliae Asiaticae 400g, Radix Musae 500g; Get Cortex Phellodendri, Radix Achyranthis Bidentatae, Herba Taraxaci, Herba Portulacae, Radix Toddaliae Asiaticae, Radix Musae with the alcohol reflux of 10 times of amounts 50% 2 times, each 2 hours, filter, merging filtrate, the thick paste of recovery ethanol and simmer down to relative density 1.2 is put cold, Venenum Bufonis is dissolved in ethanol and Rhizoma Coptidis powder, Borneolum Syntheticum, Mentholum, grind to fusing, mixing gets medical material mixture, standby; With the hydrophilic high molecular material is substrate, adds suitable filler (Kaolin, bentonite, zinc oxide, titanium dioxide) according to routine techniques; Firming agent or cross-linking agent (aluminium oxide, aluminum/EDTA, aluminum sulfate, aluminum acetate, glycine aluminum); Cross-linking regulator (citric acid, tartaric acid, gluconic acid, EDTA); Wetting agent (glycerol, sorbitol, propylene glycol); Percutaneous absorption enhancer (methyl salicylate, Camphora, Mentholum, plant extract) stirring and evenly mixing, with standby medical material mixture and substrate mixing, abundant stirring and evenly mixing, will mount respectively material, medical mylar and spice are packed in the patch spreading equipment, adjuvant rolls; After the shaping, cut into 100 * 50mm sheet, microwave sterilizating, packing, sealing, packing is promptly.
Embodiments of the invention 2: take by weighing Cortex Phellodendri 400g, Rhizoma Coptidis 50g, Herba Taraxaci 300g, Radix Achyranthis Bidentatae 400g, Borneolum Syntheticum 40g preparation, preparation method is: get Cortex Phellodendri, Radix Achyranthis Bidentatae, Herba Taraxaci, with the alcohol reflux of 10 times of amounts 80% 2 times, each 2 hours, filter, merging filtrate, reclaim the thick paste of ethanol and simmer down to relative density 1.2, put cold, Rhizoma Coptidis powder and Borneolum Syntheticum grind mixing, get the medical material mixture, according to the technology of existing pharmaceuticals industry, the medical material mixture that obtains is become the plaster preparation according to prior art for preparing again.
Embodiments of the invention 3: it is by Cortex Phellodendri 800g, Rhizoma Coptidis 80g, Herba Taraxaci 700g, Radix Achyranthis Bidentatae 800g, Borneolum Syntheticum 80g preparation: preparation method is: get Cortex Phellodendri, Radix Achyranthis Bidentatae, Herba Taraxaci, measure 40% alcohol reflux 2 times with 10 times, each 2 hours, filter, merging filtrate, reclaim the thick paste of ethanol and simmer down to relative density 1.2, put coldly, Rhizoma Coptidis powder and Borneolum Syntheticum grind to the pulverizing mixing, the medical material mixture, with the medical material mixture that obtains according to prior art for preparing Cheng Babu (cream) agent.
Embodiments of the invention 4: get Cortex Phellodendri 400g, Rhizoma Coptidis 50g, Herba Taraxaci 300g, Radix Achyranthis Bidentatae 400g, Borneolum Syntheticum 40g, Herba Portulacae 300g, flying dragon blood palm 300g, Radix Musae 400g, Mentholum 40g, preparation method is: with Cortex Phellodendri, Radix Achyranthis Bidentatae, Herba Taraxaci, Herba Portulacae, Radix Toddaliae Asiaticae, Radix Musae is with 10 times of amount alcohol reflux of 60% 2 times, each 2 hours, filter, merging filtrate, reclaim the thick paste of ethanol and simmer down to relative density 1.2, put cold, Venenum Bufonis is dissolved in ethanol and Rhizoma Coptidis powder, Borneolum Syntheticum, Mentholum, grind to fusing, mixing gets the medical material mixture, standby; With the aqueous high molecular gel is substrate, adds suitable filler, firming agent, stirring and evenly mixing, with standby medical material mixture and substrate mixing, abundant stirring and evenly mixing, will mount respectively material, medical mylar and spice are packed in the patch spreading equipment, adjuvant rolls.After the shaping, dicing, microwave sterilizating, packing, sealing, packing is promptly.
Embodiments of the invention 5: take by weighing Cortex Phellodendri 800g, Rhizoma Coptidis 80g, Herba Taraxaci 700g, Radix Achyranthis Bidentatae 800g, Borneolum Syntheticum 80g, Herba Portulacae 700g, the flying dragon blood palm 700g, Radix Musae 800g, Mentholum 80g; Preparation method is: get Cortex Phellodendri, Radix Achyranthis Bidentatae, Herba Taraxaci, Herba Portulacae, Radix Toddaliae Asiaticae, Radix Musae with the alcohol reflux of 10 times of amounts 65% 2 times, each 2 hours, filter, merging filtrate, the thick paste of recovery ethanol and simmer down to relative density 1.2 is put cold, Venenum Bufonis is dissolved in ethanol and Rhizoma Coptidis powder, Borneolum Syntheticum, Mentholum, grind to fusing, mixing gets medical material mixture, standby; Is substrate according to prior art with rubber, resin glue or pressure sensitive adhesive with the medical material mixture that obtains, and is made into paster.
Claims (8)
1, a kind of Chinese medicine for external application for the treatment of gout is characterized in that: calculate according to components by weight percent, it mainly is prepared from by Cortex Phellodendri 400-800, Rhizoma Coptidis 50-80, Herba Taraxaci 300-700, Radix Achyranthis Bidentatae 400-800, Borneolum Syntheticum 40-80.
2, the preparation method of the Chinese medicine for external application of treatment gout as claimed in claim 1, it is characterized in that: get Cortex Phellodendri, Radix Achyranthis Bidentatae, Herba Taraxaci with the alcohol reflux of 10 times of amounts 40%～80% 2 times, each 2 hours, filter merging filtrate, the thick paste of recovery ethanol and simmer down to relative density 1.2, put cold, Rhizoma Coptidis powder is broken into powder and Borneolum Syntheticum grinds to fusing, with the thick paste mixing that obtains, medical material mixture, standby; With standby medical material mixture and substrate mixing, fully stirring and evenly mixing is coated with and spreads or roll, and after the shaping, cuts into the sheet of certain specification, packing, and sealing, packing is promptly.
3, according to the Chinese medicine for external application of the described treatment gout of claim 1, it is characterized in that: calculate according to components by weight percent, it mainly is prepared from by Cortex Phellodendri 400-800, Rhizoma Coptidis 50-80, Herba Taraxaci 300-700, Radix Achyranthis Bidentatae 400-800, Borneolum Syntheticum 40-80, Herba Portulacae 300-700, the flying dragon blood palm 300-700, Radix Musae 400-800, Mentholum 40-80.
4, the preparation method of the Chinese medicine for external application of treatment gout as claimed in claim 3, it is characterized in that: get Cortex Phellodendri, Radix Achyranthis Bidentatae, Herba Taraxaci, Herba Portulacae, Radix Toddaliae Asiaticae, Radix Musae with the alcohol reflux of 10 times of amounts 40%～80% 2 times, each 2 hours, filter merging filtrate, the thick paste of recovery ethanol and simmer down to relative density 1.2, put cold, Rhizoma Coptidis powder grinds to fusing with Borneolum Syntheticum, Mentholum after being broken into powder, with the thick paste mixing that obtains, gets medical material mixture, standby; With standby medical material mixture and substrate mixing, fully stirring and evenly mixing is coated with and spreads or roll, and after the shaping, cuts into the sheet of certain specification, packing, and sealing, packing is promptly.
5, according to the Chinese medicine for external application of claim 1 or 3 described treatment gouts, it is characterized in that: it is mainly made by Cortex Phellodendri 500g, Rhizoma Coptidis powder 50g, Radix Achyranthis Bidentatae 500g, Herba Taraxaci 400g, Herba Portulacae 400g, Venenum Bufonis 20g, Borneolum Syntheticum 40g, Mentholum 40g, Radix Toddaliae Asiaticae 400g, Radix Musae 500g.
6, according to the Chinese medicine for external application of claim 1,3 or 5 described treatment gouts, it is characterized in that: described external preparation comprises: patch, plaster, cataplasma, crust cloth cream, inferior quick glue unguentum, rubber-emplastrum, transdermal patch, gel adhesive.
7, the preparation method of the Chinese medicine for external application of treatment gout as claimed in claim 5, it is characterized in that: get Cortex Phellodendri, Radix Achyranthis Bidentatae, Herba Taraxaci, Herba Portulacae, Radix Toddaliae Asiaticae, Radix Musae with the alcohol reflux of 10 times of amounts 40%～80% 2 times, each 2 hours, filter merging filtrate, the thick paste of recovery ethanol and simmer down to relative density 1.2, put cold, Venenum Bufonis is dissolved in ethanol and Rhizoma Coptidis powder, Borneolum Syntheticum, Mentholum grind to fusing, with the thick paste mixing that obtains, gets medical material mixture, standby; With standby medical material mixture and substrate mixing, fully stirring and evenly mixing is coated with and spreads or roll, and after the shaping, cuts into the sheet of certain specification, packing, and sealing, packing is promptly.
8, according to the preparation method of the Chinese medicine for external application of the described treatment gout of claim 7, it is characterized in that: the medical material mixture that obtains is become the plaster preparation according to prior art for preparing, cataplasma or crust cloth cream, or be substrate with resin glue or pressure sensitive adhesive, be made into paster, with rubber is substrate, is made into paster or gel adhesive.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100404571A CN1274342C (en) | 2004-08-13 | 2004-08-13 | Preparation for external use of Chinese traditional medicine for treating gout and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100404571A CN1274342C (en) | 2004-08-13 | 2004-08-13 | Preparation for external use of Chinese traditional medicine for treating gout and preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1626205A true CN1626205A (en) | 2005-06-15 |
| CN1274342C CN1274342C (en) | 2006-09-13 |
Family
ID=34763614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100404571A Expired - Fee Related CN1274342C (en) | 2004-08-13 | 2004-08-13 | Preparation for external use of Chinese traditional medicine for treating gout and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1274342C (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102920799A (en) * | 2012-11-21 | 2013-02-13 | 翁文庚 | Externally coated medicine for treating gout and preparation method thereof |
| CN103585604A (en) * | 2013-11-13 | 2014-02-19 | 张立主 | Medicament for treating acute gouty arthritis and use method thereof |
| CN103655786A (en) * | 2014-01-08 | 2014-03-26 | 黄金标 | Traditional Chinese medicine composition for treating hyperuricemia and gout |
| CN104887869A (en) * | 2015-05-24 | 2015-09-09 | 太仓思瑞生物科技有限公司 | Plaster for treating osteoarthritis |
| CN104887868A (en) * | 2015-05-24 | 2015-09-09 | 太仓思瑞生物科技有限公司 | Plaster for treating arthritis |
| CN107029034A (en) * | 2017-06-08 | 2017-08-11 | 福建中医药大学附属康复医院 | A kind of external-applied ointment for treating urarthritis |
| CN107951942A (en) * | 2017-12-05 | 2018-04-24 | 张淑梅 | A kind of Chinese medicine for alleviating gout symptom and plant composition and preparation method thereof |
| CN108186895A (en) * | 2018-02-09 | 2018-06-22 | 贵州苗康医药科技有限公司 | A kind of external preparation for treating gout and preparation method thereof |
| CN112245494A (en) * | 2020-10-19 | 2021-01-22 | 冯维国 | External medicine for treating gout and preparation method thereof |
-
2004
- 2004-08-13 CN CNB2004100404571A patent/CN1274342C/en not_active Expired - Fee Related
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102920799A (en) * | 2012-11-21 | 2013-02-13 | 翁文庚 | Externally coated medicine for treating gout and preparation method thereof |
| CN102920799B (en) * | 2012-11-21 | 2016-08-24 | 翁文庚 | A kind of liniment treating gout and preparation method thereof |
| CN103585604A (en) * | 2013-11-13 | 2014-02-19 | 张立主 | Medicament for treating acute gouty arthritis and use method thereof |
| CN103655786A (en) * | 2014-01-08 | 2014-03-26 | 黄金标 | Traditional Chinese medicine composition for treating hyperuricemia and gout |
| CN103655786B (en) * | 2014-01-08 | 2015-08-19 | 黄金标 | A kind of Chinese medicine composition for the treatment of hyperuricemia and gout |
| CN104887869A (en) * | 2015-05-24 | 2015-09-09 | 太仓思瑞生物科技有限公司 | Plaster for treating osteoarthritis |
| CN104887868A (en) * | 2015-05-24 | 2015-09-09 | 太仓思瑞生物科技有限公司 | Plaster for treating arthritis |
| CN107029034A (en) * | 2017-06-08 | 2017-08-11 | 福建中医药大学附属康复医院 | A kind of external-applied ointment for treating urarthritis |
| CN107951942A (en) * | 2017-12-05 | 2018-04-24 | 张淑梅 | A kind of Chinese medicine for alleviating gout symptom and plant composition and preparation method thereof |
| CN108186895A (en) * | 2018-02-09 | 2018-06-22 | 贵州苗康医药科技有限公司 | A kind of external preparation for treating gout and preparation method thereof |
| CN112245494A (en) * | 2020-10-19 | 2021-01-22 | 冯维国 | External medicine for treating gout and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1274342C (en) | 2006-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1768812A (en) | Medicinal composition for removing dampness to relieve itching and its preparation method and uses | |
| CN1714675A (en) | Natto powder and preparing method and health food containing such natto powder | |
| MXPA04011089A (en) | Fenugreek seed bio-active compositions and methods for extracting same. | |
| CN1709445A (en) | Tibetan medicine for major functions of acute-chronic sprain-contusion, rheumatism, rheumatoid diseases, and its preparing method | |
| CN1457808A (en) | Iron scale dendrobium compound preposition and preparation and use | |
| CN101036677A (en) | Compound notoginseng cataplasm | |
| CN108743500A (en) | Not only oral administration but also can external application beautifying face and moistering lotion compound peptide functional food and preparation method thereof | |
| CN1626205A (en) | Preparation for external use of Chinese traditional medicine for treating gout and preparation method | |
| CN1281230C (en) | Medicine composition for curing burn, scald and mucocutaneous ulcer | |
| CN1735420A (en) | Indian herbal soft drink | |
| CN100341529C (en) | Combination of Tibet medicine of containing salt and possessing medicinal effect health care, and preparation metohd | |
| CN1772136A (en) | Medicine composition for treating soft tissue damage and osteoarthropathy and its prepn process | |
| CN1879766A (en) | Medicine for treating rheumatism and preparation method thereof | |
| CN1053568C (en) | Herbal medicine health cosmetic series products and its preparing method | |
| CN1899587A (en) | Plaster for treating scapulohumeral periarthritis, arthritis, etc. and its preparing method | |
| CN1183841C (en) | Anti-fatigue male's health tea its production process | |
| CN1623598A (en) | Volatile extraction for promoting falling asleep and improving sleep quality and its product for external use | |
| CN110507712B (en) | Externally applied Chinese pulsatilla root extract for treating arthritis and preparation method thereof | |
| DK201670336A1 (en) | A Barbados aloe scar eliminating ointment | |
| CN105496934A (en) | Cactus mask for treating acne and preparation method | |
| CN1176697C (en) | Antisenility medicine composition and its prepn | |
| CN1792370A (en) | External use prepns. for wind-dispelling, removing-obstruction in channels to relieve pain | |
| Dutt | A study of patenting activity in Aloe vera | |
| JP5514390B2 (en) | Life extension agent made from cereals and beans other than rice | |
| CN1110910A (en) | Slim cosmetics and its prodn. method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: GUIZHOU MIAOKANG PHARMACEUTICAL TECHNOLOGY CO., LT Free format text: FORMER OWNER: ZHU QIN Effective date: 20150724 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20150724 Address after: 550014, Guiyang, Guizhou province Baiyun District Town Patentee after: Guizhou Miao Kang Pharmaceutical Technology Co., Ltd Address before: 550002 Guizhou city of Guiyang Province peach building 25 floor C block Patentee before: Zhu Qin |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060913 Termination date: 20170813 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |